VolitionRX Ltd
VNRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.75M
Close$
$1.02
191.5% upside
Current Fair Value
191.5% upsideUndervalued by 191.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.75 Million |
|---|---|
| Enterprise Value | $2.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.4 |
| Beta | 1.14 |
| Outstanding Shares | 9,154,815 |
Return
| Return on Equity | 127.90% |
|---|---|
| Return on Assets | -308.88% |
| Return on Invested Capital | -264.57% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | -0.7 |
| Price to Sales | - |
| Price to Book Ratio | -0.12 |
| Enterprise Value to Revenue | 1.18 |
| Enterprise Value to EBIT | 0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.67 |
| Debt to Equity | -0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$1.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$554,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.09%▲ 4.84% |
|---|---|
| Total Invested | $2.61M▼ 42.31% |
| Investors Holding | 26▼ 5.00% |
ESG Score
No data
About VolitionRX Ltd
65 employeesVolition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients...